Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose amoxicillin + vonoprazan dual therapy vs bismuth + furazolidone quadruple therapy for remedial Helicobacter pylori eradication
ChiCTR2100052604Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vonoprazan, amoxicillin, furazolidone and bismuth subsalicylate in Helicobacter pylori infection (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Helicobacter pylori eradication by 13C urea breath test. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
vonoprazanamoxicillinfurazolidonebismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2100052604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052604.